Minori Rosales
Chief Tech/Sci/R&D Officer chez COMPASS THERAPEUTICS, INC.
Profil
Minori Rosales is a Senior Vice President & Head-Clinical Development at Compass Therapeutics, Inc. She previously worked as a Vice President at MedImmune LLC from 2017 to 2018, as a Vice President-Clinical Research at MacroGenics, Inc. from 2018 to 2022, and as a Chief Development Officer at Sesen Bio, Inc. from 2022 to 2023.
Rosales holds a doctorate degree from Yamaguchi University and Kansai Medical University.
Postes actifs de Minori Rosales
| Sociétés | Poste | Début |
|---|---|---|
| COMPASS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2023 |
Anciens postes connus de Minori Rosales
| Sociétés | Poste | Fin |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2023 |
| MACROGENICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/01/2018 |
Formation de Minori Rosales
| Yamaguchi University | Doctorate Degree |
| Kansai Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| COMPASS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
